Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes - PubMed

Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes

H Harashima et al. Pharm Res. 1994 Mar.

Abstract

The objective of this study was to differentiate the roles of opsonins and phagocytic cells in the size-dependent hepatic uptake of liposomes in the submicron region. The extent of opsonization decreased with the decrease in size of liposomes (from 800 to 200 nm in diameter) and no enhancement of uptake was observed at 200 nm. There was no effect of liposome size on the uptake of unopsonized liposomes. Serum was pretreated with empty liposomes of each size and its opsonic activity was measured in the perfused liver. The small liposomes could not consume the opsonic activity, while the larger ones did so substantially. These results suggest that opsonins bind to liposomes depending on the size of liposomes and phagocytic cells take up liposomes in proportion to the extent of opsonization. Size-dependent liposome degradation in serum was also found, which was consistent with the size-dependent complement activation, because liposomes with this composition have been shown to be degraded by complement. The mechanism of opsonization was examined by treating serum at 56 degrees C for 30 min or with anti-C3 antiserum. Since both treatments inhibited the opsonic activity, the hepatic uptake of liposomes is considered to occur via complement receptor. In conclusion, the size of liposomes affected complement recognition, and the liposomes were taken up by the liver depending on the extent of opsonization.

Similar articles

• The complement- but not mannose receptor-mediated phagocytosis is involved in the hepatic uptake of cetylmannoside-modified liposomes in situ.

  Matsuo H, Funato K, Harashima H, Kiwada H. Matsuo H, et al. J Drug Target. 1994;2(2):141-6. doi: 10.3109/10611869409015902. J Drug Target. 1994. PMID: 8069591

• Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin.

  Liu D, Liu F, Song YK. Liu D, et al. Biochim Biophys Acta. 1995 Apr 12;1235(1):140-6. doi: 10.1016/0005-2736(95)00005-n. Biochim Biophys Acta. 1995. PMID: 7718601

• Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats.

  Harashima H, Huong TM, Ishida T, Manabe Y, Matsuo H, Kiwada H. Harashima H, et al. Pharm Res. 1996 Nov;13(11):1704-9. doi: 10.1023/a:1016401025747. Pharm Res. 1996. PMID: 8956338

• Serum opsonins and liposomes: their interaction and opsonophagocytosis.

  Patel HM. Patel HM. Crit Rev Ther Drug Carrier Syst. 1992;9(1):39-90. Crit Rev Ther Drug Carrier Syst. 1992. PMID: 1544174 Review.

• Liposome opsonization.

  Yan X, Scherphof GL, Kamps JA. Yan X, et al. J Liposome Res. 2005;15(1-2):109-39. doi: 10.1081/lpr-64971. J Liposome Res. 2005. PMID: 16194930 Review.

Cited by

• Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study.

  Bai S, Gupta V, Ahsan F. Bai S, et al. Eur J Pharm Sci. 2009 Sep 10;38(2):165-71. doi: 10.1016/j.ejps.2009.07.002. Epub 2009 Jul 16. Eur J Pharm Sci. 2009. PMID: 19616095 Free PMC article.

• Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism.

  Harashima H, Komatsu S, Kojima S, Yanagi C, Morioka Y, Naito M, Kiwada H. Harashima H, et al. Pharm Res. 1996 Jul;13(7):1049-54. doi: 10.1023/a:1016058724452. Pharm Res. 1996. PMID: 8842043

• Development of Novel Lipid-Based Formulations for Water-Soluble Vitamin C versus Fat-Soluble Vitamin D3.

  Chen J, Dehabadi L, Ma YC, Wilson LD. Chen J, et al. Bioengineering (Basel). 2022 Dec 19;9(12):819. doi: 10.3390/bioengineering9120819. Bioengineering (Basel). 2022. PMID: 36551025 Free PMC article.

• Albumin-Based Nanocarriers for the Simultaneous Delivery of Antioxidant Gene and Phytochemical to Combat Oxidative Stress.

  Naqvi S, Khanadeev VA, Khlebtsov BN, Khlebtsov NG, Deore MS, Packirisamy G. Naqvi S, et al. Front Cell Dev Biol. 2022 Aug 12;10:846175. doi: 10.3389/fcell.2022.846175. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36035986 Free PMC article.

• Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.

  Jubair L, Fallaha S, McMillan NAJ. Jubair L, et al. Mol Ther. 2019 Dec 4;27(12):2091-2099. doi: 10.1016/j.ymthe.2019.08.012. Epub 2019 Aug 29. Mol Ther. 2019. PMID: 31537455 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal